[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 38, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 832920, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 730050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 69, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sriram  Ryali M.B.A.", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer & Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tina  Albertson M.D., Ph.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.72, "open": 1.7, "dayLow": 1.645, "dayHigh": 1.7199, "regularMarketPreviousClose": 1.72, "regularMarketOpen": 1.7, "regularMarketDayLow": 1.645, "regularMarketDayHigh": 1.7199, "payoutRatio": 0.0, "beta": 2.604, "forwardPE": -0.85427135, "volume": 772969, "regularMarketVolume": 772969, "averageVolume": 2324890, "averageVolume10days": 1023760, "averageDailyVolume10Day": 1023760, "bid": 1.22, "ask": 2.13, "bidSize": 2, "askSize": 2, "marketCap": 158895680, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.535, "allTimeHigh": 32.645, "allTimeLow": 0.66, "priceToSalesTrailing12Months": 17.094748, "fiftyDayAverage": 2.0705, "twoHundredDayAverage": 1.6165, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 37100664, "profitMargins": 0.0, "floatShares": 84428744, "sharesOutstanding": 93468038, "sharesShort": 6240758, "sharesShortPriorMonth": 5618833, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0668, "heldPercentInsiders": 0.09778, "heldPercentInstitutions": 0.38959, "shortRatio": 6.2, "shortPercentOfFloat": 0.0699, "impliedSharesOutstanding": 93468038, "bookValue": 1.518, "priceToBook": 1.1198946, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -157127008, "trailingEps": -1.7, "forwardEps": -1.99, "enterpriseToRevenue": 3.991, "enterpriseToEbitda": -0.273, "52WeekChange": 0.068323016, "SandP52WeekChange": 0.17354333, "quoteType": "EQUITY", "currentPrice": 1.7, "targetHighPrice": 32.0, "targetLowPrice": 4.0, "targetMeanPrice": 11.125, "targetMedianPrice": 8.5, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 147259008, "totalCashPerShare": 1.576, "ebitda": -135692992, "totalDebt": 25464000, "quickRatio": 5.353, "currentRatio": 5.542, "totalRevenue": 9295000, "debtToEquity": 17.952, "revenuePerShare": 0.1, "returnOnAssets": -0.32411, "returnOnEquity": -0.74283, "grossProfits": -119263000, "freeCashflow": -76102000, "operatingCashflow": -125638000, "revenueGrowth": 0.086, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -13.375799, "financialCurrency": "USD", "symbol": "CRBU", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "regularMarketChangePercent": -1.16279, "regularMarketPrice": 1.7, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627047000000, "postMarketChangePercent": -2.0823548, "postMarketPrice": 1.6646, "postMarketChange": -0.035400033, "regularMarketChange": -0.02, "regularMarketDayRange": "1.645 - 1.7199", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2324890, "fiftyTwoWeekLowChange": 1.04, "fiftyTwoWeekLowChangePercent": 1.5757575, "fiftyTwoWeekRange": "0.66 - 3.535", "fiftyTwoWeekHighChange": -1.835, "fiftyTwoWeekHighChangePercent": -0.51909477, "fiftyTwoWeekChangePercent": 6.8323016, "corporateActions": [], "postMarketTime": 1766793665, "regularMarketTime": 1766782801, "exchange": "NMS", "messageBoardId": "finmb_272189231", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "earningsTimestamp": 1762981200, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.7, "epsForward": -1.99, "fiftyDayAverageChange": -0.37049985, "fiftyDayAverageChangePercent": -0.17894222, "twoHundredDayAverageChange": 0.08350003, "twoHundredDayAverageChangePercent": 0.051654827, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-23", "cryptoTradeable": false, "marketState": "CLOSED", "displayName": "Caribou Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]